GO:0043310 negative regulation of eosinophil degranulation: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043310 describes any process that stops, prevents, or reduces the rate of eosinophil degranulation, the release of cytotoxic granule contents from eosinophils.
• Eosinophil degranulation is a central effector mechanism in allergic inflammation and host defense, and its negative regulation is critical for limiting tissue damage [2, 5].
• Cyclic AMP (cAMP) signaling is a well-established negative regulator of eosinophil degranulation, acting through multiple intracellular pathways [4, 6].
• Endogenous phospholipase A2 activity modulates eosinophil degranulation, with inhibition reducing granule release.
• Mast cell-derived mediators and IgE-dependent activation can promote eosinophil degranulation, highlighting the need for counter-regulatory mechanisms.
• Histamine, produced by IL-33-stimulated mast cells, can negatively regulate IL-33-induced eosinophilia, illustrating a broader homeostatic control of eosinophil responses.
Description
Eosinophils are granulocytic leukocytes that play essential roles in host defense against parasites and in the pathogenesis of allergic diseases such as asthma and atopic dermatitis. Their effector functions are largely mediated by the release of granule proteins, a process known as degranulation, which can cause significant tissue damage when dysregulated [2, 5]. The Gene Ontology term GO:0043310, negative regulation of eosinophil degranulation, encompasses any process that stops, prevents, or reduces the rate of this granule exocytosis. Understanding the molecular mechanisms that restrain eosinophil degranulation is crucial for developing therapies that mitigate eosinophil-associated pathology without compromising beneficial immunity [4, 6]. This article synthesizes current knowledge on the negative regulation of eosinophil degranulation, drawing on authoritative GO annotations and published experimental evidence to provide a research-grade overview for scientists and clinicians.
negative regulation of eosinophil degranulation At A Glance
| GO ID | GO:0043310 |
|---|---|
| GO term | negative regulation of eosinophil degranulation |
| Ontology | biological_process |
| Synonym | inhibition of eosinophil degranulation; downregulation of eosinophil degranulation; negative regulation of eosinophil granule exocytosis |
| Major function | Suppression of eosinophil granule exocytosis to prevent excessive tissue damage and maintain immune homeostasis [2, 4]. |
| Key regulators | Cyclic AMP (cAMP) signaling, endogenous phospholipase A2, histamine, and mast cell-derived mediators [3, 4, 6, 8]. |
| Associated cell type | Eosinophils, particularly human peripheral blood eosinophils and tissue-infiltrating eosinophils [2, 5]. |
| Disease relevance | Allergic inflammation, asthma, atopic dermatitis, and eosinophil-associated disorders [1, 5, 7]. |
| Research methods | In vitro degranulation assays, cAMP modulation, phospholipase A2 inhibition, flow cytometry, and genomic sequencing [1, 3, 4, 6]. |
What Is GO:0043310?
GO:0043310, negative regulation of eosinophil degranulation, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of eosinophil degranulation. Eosinophil degranulation is the regulated exocytosis of granule contents, including major basic protein, eosinophil peroxidase, and eosinophil cationic protein, from eosinophils. Negative regulation of this process therefore includes signaling events, molecular interactions, and cellular changes that suppress granule release, thereby limiting the extracellular deposition of cytotoxic proteins [3, 4, 6].
Why Is negative regulation of eosinophil degranulation Important in Cell Biology?
Negative regulation of eosinophil degranulation is essential for preventing collateral tissue damage during immune responses. Eosinophil granule proteins are highly cytotoxic and can injure healthy tissues if released indiscriminately [2, 5]. Dysregulation of this process contributes to the pathogenesis of allergic and inflammatory diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis [1, 5]. Moreover, understanding the negative regulatory mechanisms offers therapeutic opportunities to dampen eosinophilic inflammation without ablating beneficial eosinophil functions [4, 6]. Thus, GO:0043310 represents a critical node in immune regulation with broad implications for human health.
• Prevents excessive tissue damage from cytotoxic granule proteins during allergic inflammation [2, 5].
• Maintains immune homeostasis by balancing eosinophil effector functions [4, 6].
• Dysregulation is linked to asthma, atopic dermatitis, and other eosinophilic disorders [1, 5].
• cAMP signaling is a key negative regulatory pathway that can be pharmacologically targeted [4, 6].
• Endogenous phospholipase A2 activity modulates degranulation, offering a potential therapeutic target.
• Mast cell-eosinophil crosstalk influences degranulation, highlighting complex cellular regulation.
• Histamine from IL-33-stimulated mast cells can negatively regulate eosinophilia, revealing a homeostatic feedback loop.
• Understanding negative regulation aids in designing therapies that selectively suppress harmful eosinophil activity [1, 4].
• Relevant to endometriosis, where degranulating eosinophils contribute to pathology.
• Provides insights into primary atopic disorders and genetic drivers of eosinophil dysregulation.
What Happens During negative regulation of eosinophil degranulation?
Initiation of Negative Regulatory Signals
In simple terms: The process begins when molecules outside or inside the eosinophil send 'stop' signals to prevent granule release.
Negative regulation of eosinophil degranulation can be initiated by extracellular cues such as cAMP-elevating agents, which activate intracellular signaling cascades [4, 6]. Endogenous phospholipase A2 activity also modulates the threshold for degranulation, with its inhibition leading to reduced granule release. Additionally, mast cell-derived mediators and histamine can influence eosinophil activation states, potentially setting the stage for negative regulation [5, 8].
Intracellular Signaling Cascades
In simple terms: Inside the cell, specific signaling pathways relay the stop signal to the granule release machinery.
Cyclic AMP (cAMP) is a central second messenger that negatively regulates eosinophil degranulation. Elevation of intracellular cAMP, either by activators of adenylyl cyclase or inhibitors of phosphodiesterases, suppresses Ig-induced degranulation. cAMP modulators also affect eosinophil survival and CD11b expression, indicating broad effects on eosinophil activation. Phospholipase A2 activity is another intracellular component that regulates degranulation, as its inhibition reduces the release of granule proteins.
Inhibition of Granule Exocytosis Machinery
In simple terms: The final step is the direct blocking of the machinery that moves granules to the cell surface and releases their contents.
The exact molecular targets of cAMP and phospholipase A2 in the degranulation machinery are not fully elucidated, but evidence suggests that these pathways interfere with granule-plasma membrane fusion or cytoskeletal reorganization required for exocytosis [3, 4]. Negative regulation may also involve changes in intracellular calcium flux or activation of inhibitory kinases, though specific molecules remain to be defined [2, 6].
Feedback and Homeostatic Control
In simple terms: The body uses feedback loops to keep eosinophil degranulation in check and avoid excessive inflammation.
Histamine, released from IL-33-stimulated mast cells, can negatively regulate IL-33-induced eosinophilia, demonstrating a systemic feedback mechanism that limits eosinophil accumulation and potentially degranulation. This intercellular crosstalk highlights how negative regulation of eosinophil degranulation is integrated into broader immune homeostasis [5, 8].
Key Genes Involved in GO:0043310 negative regulation of eosinophil degranulation
The following genes and proteins have been implicated in the negative regulation of eosinophil degranulation, based on published experimental evidence.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G4A | Encodes cytosolic phospholipase A2, which modulates eosinophil degranulation; inhibition reduces granule release. | Target for anti-inflammatory strategies; studied in eosinophil activation assays. |
| ADCY | Adenylyl cyclase isoforms generate cAMP, a key negative regulator of degranulation. | cAMP modulation is a standard experimental approach to suppress eosinophil degranulation [4, 6]. |
| PDE4 | Phosphodiesterase 4 degrades cAMP; inhibition elevates cAMP and suppresses degranulation. | PDE4 inhibitors are investigated as anti-inflammatory agents. |
| PRKACA | Catalytic subunit of protein kinase A, a downstream effector of cAMP that can inhibit degranulation. | PKA activation is linked to reduced eosinophil degranulation. |
| HRH1 | Histamine receptor H1 mediates histamine effects, which can negatively regulate eosinophilia. | Histamine signaling is a potential target for modulating eosinophil responses. |
| IL33 | Interleukin-33 induces eosinophilia and mast cell activation; histamine from this axis can feedback to limit eosinophilia. | IL-33 pathway is studied in allergic inflammation models. |
| KIT | c-kit positive cells, including mast cells, produce histidine decarboxylase and histamine in response to IL-33. | c-kit+ cells are key sources of histamine that negatively regulate eosinophilia. |
| HDC | Histidine decarboxylase synthesizes histamine, which can negatively regulate IL-33-induced eosinophilia. | HDC expression is a marker of histamine-producing cells in allergic responses. |
| FCER1A | High-affinity IgE receptor alpha chain; IgE-activated mast cells promote eosinophil degranulation and adhesion. | IgE-mast cell-eosinophil axis is relevant to allergic conjunctivitis and asthma. |
| ITGB2 | CD11b integrin subunit; expression is modulated by cAMP and affects eosinophil adhesion and degranulation. | CD11b is a marker of eosinophil activation and a potential therapeutic target. |
| ALOX5 | 5-lipoxygenase pathway may interact with phospholipase A2 in regulating eosinophil mediator release. | Lipid mediator pathways are studied in eosinophil biology. |
| PTGS2 | Cyclooxygenase-2 may influence prostaglandin production and eosinophil activation. | COX-2 inhibitors are sometimes used to modulate eosinophilic inflammation. |
| GATA1 | Transcription factor essential for eosinophil development; its expression levels affect eosinophil granule content. | GATA1 is a master regulator of eosinophil lineage. |
| IL5 | Interleukin-5 promotes eosinophil survival and activation; negative regulators may counteract IL-5 signaling. | IL-5 is a key cytokine in eosinophilic asthma and a therapeutic target. |
| CCR3 | Eotaxin receptor mediating eosinophil recruitment; signaling may intersect with degranulation regulation. | CCR3 antagonists are explored for eosinophilic disorders. |
| SIGLEC8 | Inhibitory receptor on eosinophils that can suppress activation and degranulation. | SIGLEC8 is a potential target for dampening eosinophil activity. |
| ANXA1 | Annexin A1 is an anti-inflammatory protein that can inhibit eosinophil degranulation. | ANXA1 mimetics are investigated for eosinophilic inflammation. |
| PTPN6 | SHP-1 tyrosine phosphatase may negatively regulate eosinophil signaling pathways. | PTPN6 is a candidate negative regulator in hematopoietic cells. |
How Is negative regulation of eosinophil degranulation Regulated?
The negative regulation of eosinophil degranulation is controlled by multiple intracellular and extracellular mechanisms. Cyclic AMP (cAMP) serves as a major second messenger; its elevation by adenylyl cyclase activators or phosphodiesterase inhibitors suppresses Ig-induced degranulation [4, 6]. Endogenous phospholipase A2 activity also modulates degranulation, with inhibition leading to reduced granule release. Histamine, produced by IL-33-stimulated mast cells, can negatively regulate IL-33-induced eosinophilia, providing a systemic feedback loop. Additionally, mast cell-derived mediators and IgE-dependent activation can promote degranulation, highlighting the need for counter-regulatory signals. These pathways collectively maintain eosinophil homeostasis and prevent excessive tissue damage.
negative regulation of eosinophil degranulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G4A | Allergic inflammation; phospholipase A2 modulates degranulation. | Knockout or point-mutation eosinophil-like cell lines; degranulation assays. |
| PDE4 | Asthma and COPD; PDE4 inhibition elevates cAMP and suppresses degranulation. | Overexpression or knockout in primary eosinophils; cAMP assays. |
| HRH1 | Atopic dermatitis; histamine signaling affects eosinophilia. | Knock-in mice with human HRH1; IL-33 challenge models. |
| IL33 | Asthma and allergic rhinitis; IL-33 induces eosinophilia. | IL33 knockout mice; mast cell-eosinophil co-culture. |
| FCER1A | Allergic conjunctivitis; IgE-activated mast cells promote degranulation. | Knock-in human FCER1A in mast cells; conjunctival epithelial co-culture. |
Allergic Inflammation and Asthma
Eosinophil degranulation is a hallmark of allergic inflammation, contributing to airway hyperresponsiveness and tissue remodeling in asthma [2, 5]. Negative regulation of degranulation is impaired in severe asthma, leading to increased granule protein deposition and epithelial damage [1, 5]. Therapies that enhance negative regulatory pathways, such as cAMP-elevating agents, are being explored to control eosinophilic inflammation [4, 6].
Atopic Dermatitis and Primary Atopic Disorders
Primary atopic disorders (PAD) are monogenic conditions characterized by severe allergic inflammation, often involving eosinophils. Rapid identification of PAD through genomic sequencing can reveal mutations in genes that regulate eosinophil degranulation, offering personalized treatment options. Understanding negative regulation in this context may uncover new therapeutic targets.
Endometriosis
Degranulating eosinophils have been observed in human endometriosis, where they contribute to inflammation and tissue damage. Negative regulation of eosinophil degranulation may be a protective mechanism, and its dysregulation could exacerbate endometriotic lesions. Targeting eosinophil degranulation pathways is a potential therapeutic strategy for endometriosis.
From negative regulation of eosinophil degranulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate eosinophil degranulation? | CRISPR knockout of gene X in human eosinophil-like cell lines (e.g., HL-60 clone 15) followed by degranulation assays [3, 4]. |
| Does a specific point mutation in gene Y alter its inhibitory function? | CRISPR point-mutation knock-in of the mutation in eosinophil progenitors; compare degranulation. |
| Does overexpression of gene Z suppress degranulation? | Lentiviral overexpression of gene Z in primary eosinophils or cell lines; measure granule release. |
| Does a tagged version of protein W localize to granules? | CRISPR knock-in of fluorescent or epitope tag; imaging and co-localization studies. |
| Does histamine negatively regulate eosinophilia in vivo? | IL-33-challenged mice with histidine decarboxylase knockout or mast cell deficiency. |
| Does cAMP signaling modulate degranulation in primary cells? | Primary human eosinophils treated with cAMP modulators; flow cytometry for CD11b and granule proteins. |
How to Study the negative regulation of eosinophil degranulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EPO release assay | Eosinophil peroxidase release as a marker of degranulation. | Screening for inhibitors of degranulation. |
| ELISA for EDN | Eosinophil-derived neurotoxin levels in supernatants. | Quantifying degranulation in response to stimuli. |
| Flow cytometry for CD11b | Surface CD11b expression as an activation marker. | Assessing eosinophil activation state. |
| cAMP quantification | Intracellular cAMP levels after modulation [4, 6]. | Evaluating negative regulatory signaling. |
| Genomic sequencing | Mutations in genes associated with atopic disorders. | Diagnosing primary atopic disorders. |
| Live-cell imaging | Real-time granule exocytosis dynamics. | Visualizing negative regulation of degranulation. |
| Phospholipase A2 activity assay | Enzymatic activity of phospholipase A2. | Testing inhibitors that reduce degranulation. |
| Mast cell-eosinophil co-culture | Eosinophil degranulation induced by IgE-activated mast cells. | Modeling allergic inflammation. |
In Vitro Degranulation Assays
Eosinophil degranulation is commonly measured by quantifying the release of granule proteins such as eosinophil peroxidase (EPO) or eosinophil-derived neurotoxin (EDN) using colorimetric or ELISA-based assays [3, 4]. These assays can be adapted to test negative regulators by pre-treating cells with cAMP modulators or phospholipase A2 inhibitors [3, 6].
Flow Cytometry for Activation Markers
Flow cytometry can assess eosinophil activation by measuring surface markers like CD11b, which is upregulated upon activation and modulated by cAMP. This method allows simultaneous analysis of degranulation and survival, providing a comprehensive view of negative regulatory effects.
Genomic Sequencing for Primary Atopic Disorders
Clinical landmark-guided genomic sequencing enables rapid identification of mutations in genes associated with primary atopic disorders, including those regulating eosinophil degranulation. This approach can uncover novel negative regulators and guide personalized therapy.
Imaging of Granule Exocytosis
Advanced imaging techniques, such as live-cell microscopy with fluorescently tagged granule proteins, allow real-time visualization of degranulation events. These methods can reveal how negative regulators affect granule trafficking and fusion with the plasma membrane.
How CRISPR Can Be Used to Study GO:0043310 negative regulation of eosinophil degranulation
Knockout
CRISPR knockout of candidate negative regulators (e.g., PDE4, PRKACA) in eosinophil-like cell lines can reveal their role in suppressing degranulation. Loss of function is expected to increase granule release, confirming negative regulatory activity [4, 6].
Point Mutation
Introducing specific point mutations in genes such as PLA2G4A or ADCY can dissect the functional domains required for negative regulation. For example, mutations that abolish catalytic activity can test whether enzymatic function is necessary for suppressing degranulation [3, 4].
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-tagged ANXA1) allows tracking of their localization and interaction with granule membranes during negative regulation. This can identify where and when the inhibitory signal acts.
Overexpression
Overexpression of putative negative regulators (e.g., SIGLEC8, ANXA1) in eosinophils or cell lines can test whether increased levels enhance suppression of degranulation. This approach is useful for validating therapeutic targets.
How EDITGENE Supports negative regulation of eosinophil degranulation Research
Researchers studying negative regulation of eosinophil degranulation-related genes often need to determine whether a candidate gene is causally involved in suppressing granule release or is merely a bystander. CRISPR-based models provide a robust way to establish causality by precisely manipulating gene function in relevant cell types. EDITGENE offers a comprehensive suite of services to accelerate this research, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of eosinophil degranulation research.
Frequently Asked Questions About negative regulation of eosinophil degranulation
What is negative regulation of eosinophil degranulation?
It is any biological process that stops, prevents, or reduces the rate of eosinophil degranulation, the release of cytotoxic granule proteins from eosinophils.
What genes are involved in negative regulation of eosinophil degranulation?
Key genes include PLA2G4A, ADCY, PDE4, PRKACA, HRH1, and IL33, among others, based on published studies [3, 4, 6, 8].
How is eosinophil degranulation negatively regulated by cAMP?
Elevation of intracellular cAMP, via adenylyl cyclase activation or phosphodiesterase inhibition, suppresses Ig-induced eosinophil degranulation [4, 6].
What is the role of phospholipase A2 in eosinophil degranulation?
Endogenous phospholipase A2 activity modulates degranulation; its inhibition reduces granule release, suggesting a regulatory role.
Can histamine negatively regulate eosinophil degranulation?
Histamine, produced by IL-33-stimulated mast cells, can negatively regulate IL-33-induced eosinophilia, indirectly limiting eosinophil responses.
What diseases are associated with dysregulated eosinophil degranulation?
Asthma, atopic dermatitis, primary atopic disorders, and endometriosis are linked to eosinophil degranulation and its dysregulation [1, 5, 7].
How can I study negative regulation of eosinophil degranulation in the lab?
Common methods include in vitro degranulation assays, flow cytometry for CD11b, cAMP quantification, and CRISPR-based gene editing [3, 4, 6].
What CRISPR models are available for studying eosinophil degranulation?
Knockout, point mutation, knock-in, and overexpression models in eosinophil-like cell lines or primary cells can be generated [2, 4].
What is the GO ID for negative regulation of eosinophil degranulation?
The GO ID is GO:0043310.
Why is negative regulation of eosinophil degranulation important?
It prevents excessive tissue damage from cytotoxic granule proteins and maintains immune homeostasis, with implications for allergic and inflammatory diseases [2, 5].
Conclusion
Negative regulation of eosinophil degranulation (GO:0043310) is a critical biological process that restrains the release of cytotoxic granule proteins from eosinophils, thereby protecting tissues from damage during immune responses [2, 5]. Key regulatory pathways include cAMP signaling, phospholipase A2 activity, and histamine-mediated feedback [3, 4, 6, 8]. Dysregulation of this process contributes to allergic inflammation, asthma, atopic dermatitis, and endometriosis [1, 5, 7]. Continued research using CRISPR-based models and advanced molecular techniques will further elucidate the mechanisms and identify therapeutic targets to modulate eosinophil degranulation in disease.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Lacy P et al.. 2021. Molecular Biology of Eosinophils: Introduction.. Methods Mol Biol 2241:1-14 PMID: 33486723
- 3. White SR et al.. 1993. Regulation of human eosinophil degranulation and activation by endogenous phospholipase A2.. J Clin Invest 91(5):2118-25 PMID: 8387540
- 4. Kita H et al.. 1991. Regulation of Ig-induced eosinophil degranulation by adenosine 3',5'-cyclic monophosphate.. J Immunol 146(8):2712-8 PMID: 1707917
- 5. Cook EB et al.. 2004. The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells.. Ann Allergy Asthma Immunol 92(1):65-72 PMID: 14756467
- 6. Momose T et al.. 1998. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression.. Int Arch Allergy Immunol 117(2):138-45 PMID: 9784658
- 7. Blumenthal RD et al.. 2000. Degranulating eosinophils in human endometriosis.. Am J Pathol 156(5):1581-8 PMID: 10793070
- 8. Bando K et al.. 2023. IL-33 induces histidine decarboxylase, especially in c-kit(+) cells and mast cells, and roles of histamine include negative regulation of IL-33-induced eosinophilia.. Inflamm Res 72(3):651-667 PMID: 36723628
